ORYZON to Provide Corporate Progress Updates at Several Events in October
October 02, 2023 08:00 ET
|
Oryzon Genomics, S.A.
East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023)Investor Access 2023 EventJefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2nd...
ORYZON to Give Updates on Corporate Progress in September
September 05, 2023 08:00 ET
|
Oryzon Genomics, S.A.
H.C. Wainwright Global Investment Conference in NYCSachs Annual Biotech in Europe Forum in BaselThird Annual Global CMT Research Convention in BostonBioSpain-2023 in Barcelona MADRID, Spain and...
Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
July 26, 2023 08:00 ET
|
Oryzon Genomics, S.A.
Full recruitment secures the target number of completer patientsMultiple primary endpoints include reduction in agitation and aggression and overall disease improvementTopline efficacy data expected...
ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
July 24, 2023 12:47 ET
|
Oryzon Genomics, S.A.
Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the...
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
July 05, 2023 08:00 ET
|
Oryzon Genomics, S.A.
Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patientsPORTICO plans to recruit 188...
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
June 27, 2023 08:00 ET
|
Oryzon Genomics, S.A.
All resolutions were approved.35% of the issued shares represented. MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...
Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
June 21, 2023 08:00 ET
|
Oryzon Genomics, S.A.
Comprehensively reversed disease progression symptoms in a CMT mice modelSelected for an oral presentationA highly selective and safe HDAC-6 inhibitorTo start IND-enabling studies soon MADRID,...
ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
May 30, 2023 08:00 ET
|
Oryzon Genomics, S.A.
Selected for Oral PresentationStudy done in the CMT1A mouse modelSupported by the CMT Research Foundation MADRID, Spain and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...
ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting
May 17, 2023 08:00 ET
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023
May 10, 2023 09:59 ET
|
Oryzon Genomics, S.A.
Positive results from interim analysis of vafidemstat's PORTICO Phase IIb trial in Borderline Personality DisorderRecruiting patients in FRIDA trial with iadademstat in combination with gilteritinib...